Related Experiment Video
Updated: Mar 26, 2026
07:13
Author Spotlight: High-Quality Quantum Dot Nanobeads for Sensitive Fluorescent Lateral Flow Immunoassays
Published on: June 28, 2024
2.4K
Bead-based microarray immunoassay for lung cancer biomarkers using quantum dots as labels.
Lifen Liu1, Simin Wu1, Fengxiang Jing1
1State Key Laboratory of Functional Materials for Informatics, Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences, 865 Changning Road, Shanghai 200050, PR China.
Biosensors & Bioelectronics
|February 8, 2016
Summary
This study introduces a novel multiplex immunoassay system on a single chip for detecting three lung cancer biomarkers simultaneously. The cost-effective, easy-to-operate system offers high sensitivity and a wide dynamic range for early cancer detection.
Area of Science:
- Biomedical Engineering
- Analytical Chemistry
- Nanotechnology
Background:
- Multiplex immunoassays are crucial for detecting multiple biomarkers simultaneously.
- Existing microfluidic systems often require complex fabrication and expensive equipment.
- There is a need for integrated, cost-effective, and user-friendly platforms for biomarker detection.
Purpose of the Study:
- To develop an integrated multiplex immunoassay system combining suspension and planar microarray formats.
- To enable simultaneous detection of three key lung cancer biomarkers using a single chip.
- To create a cost-effective and user-friendly platform for on-chip biomarker analysis.
Main Methods:
- Utilized soft lithography to fabricate a polydimethylsiloxane (PDMS) chip integrating suspension and planar microarray formats.
- Employed magnetic beads and quantum dot (QD) probes for sandwich immunoassay in the suspension format.
- Fabricated micro-wells in PDMS to create a microbead array for the planar microarray format.
Main Results:
- Successfully detected three lung cancer biomarkers: carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), and neuron-specific enolase (NSE) in human serum.
- Achieved a wide linear dynamic range (1.03-111 ng/mL for CEA/CYFRA21-1; 9.26-1000 ng/mL for NSE).
- Demonstrated low detection limits (CEA: 0.19 ng/mL; CYFRA21-1: 0.97 ng/mL; NSE: 0.37 ng/mL) with high sensitivity.
Conclusions:
- The developed on-chip multiplexing sandwich assay system is effective for simultaneous detection of biomarker proteins.
- The PDMS-based microfluidic chip offers a cost-effective, easy-to-operate, and sensitive alternative to existing systems.
- This technology holds significant potential for early lung cancer diagnosis and personalized medicine.
